Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.51 Million CAD | 18.94% |
| 2022 | -3.53 Million CAD | -54.3% |
| 2021 | -2.28 Million CAD | 44.58% |
| 2020 | -4.12 Million CAD | 7.07% |
| 2019 | -4.44 Million CAD | -387.24% |
| 2018 | -911.98 Thousand CAD | 63.37% |
| 2017 | -2.48 Million CAD | 15.14% |
| 2016 | -2.93 Million CAD | 16.11% |
| 2015 | -3.49 Million CAD | -0.45% |
| 2014 | -3.48 Million CAD | -32.08% |
| 2013 | -2.63 Million CAD | 12.72% |
| 2012 | -3.02 Million CAD | -39.22% |
| 2011 | -2.16 Million CAD | -102.82% |
| 2010 | -1.06 Million CAD | 12.78% |
| 2009 | -1.22 Million CAD | -838.3% |
| 2008 | -130.7 Thousand CAD | 45.1% |
| 2007 | -238.06 Thousand CAD | -3967650.0% |
| 2006 | -6.00 CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -534.03 Thousand CAD | 31.55% |
| 2024 Q1 | -780.12 Thousand CAD | -36.52% |
| 2024 Q3 | -664.87 Thousand CAD | -22.77% |
| 2023 Q2 | -757.54 Thousand CAD | -22.08% |
| 2023 FY | -2.86 Million CAD | 18.94% |
| 2023 Q1 | -620.52 Thousand CAD | -71.21% |
| 2023 Q4 | -571.42 Thousand CAD | -26.0% |
| 2023 Q3 | -453.52 Thousand CAD | 40.13% |
| 2022 Q4 | -362.43 Thousand CAD | 4.98% |
| 2022 Q3 | -381.41 Thousand CAD | 49.68% |
| 2022 FY | -3.53 Million CAD | -54.3% |
| 2022 Q1 | -2.02 Million CAD | -476.4% |
| 2022 Q2 | -757.99 Thousand CAD | 62.65% |
| 2021 Q1 | -663.1 Thousand CAD | -63.88% |
| 2021 FY | -2.28 Million CAD | 44.58% |
| 2021 Q2 | -776.5 Thousand CAD | -17.1% |
| 2021 Q4 | -352.08 Thousand CAD | 72.13% |
| 2021 Q3 | -1.26 Million CAD | -62.71% |
| 2020 Q3 | -618 Thousand CAD | 1.73% |
| 2020 Q4 | -404.62 Thousand CAD | 34.53% |
| 2020 Q2 | -628.9 Thousand CAD | 74.64% |
| 2020 Q1 | -2.48 Million CAD | -93.92% |
| 2020 FY | -4.12 Million CAD | 7.07% |
| 2019 Q2 | -1.27 Million CAD | -136.48% |
| 2019 Q3 | -1.34 Million CAD | -5.7% |
| 2019 FY | -4.44 Million CAD | -387.24% |
| 2019 Q4 | -1.27 Million CAD | 5.19% |
| 2019 Q1 | -539.63 Thousand CAD | -15.62% |
| 2018 FY | -911.98 Thousand CAD | 63.37% |
| 2018 Q4 | -466.75 Thousand CAD | -387.53% |
| 2018 Q1 | -69.17 Thousand CAD | 89.42% |
| 2018 Q2 | -564.28 Thousand CAD | -715.72% |
| 2018 Q3 | 162.33 Thousand CAD | 128.77% |
| 2017 FY | -2.48 Million CAD | 15.14% |
| 2017 Q3 | -599.12 Thousand CAD | 13.53% |
| 2017 Q2 | -692.9 Thousand CAD | -27.34% |
| 2017 Q1 | -544.13 Thousand CAD | 37.59% |
| 2017 Q4 | -653.65 Thousand CAD | -9.1% |
| 2016 Q2 | -387.48 Thousand CAD | 49.66% |
| 2016 Q4 | -871.86 Thousand CAD | 3.65% |
| 2016 Q3 | -904.9 Thousand CAD | -133.53% |
| 2016 FY | -2.93 Million CAD | 16.11% |
| 2016 Q1 | -769.79 Thousand CAD | -59.36% |
| 2015 FY | -3.49 Million CAD | -0.45% |
| 2015 Q1 | -1 Million CAD | -111.57% |
| 2015 Q4 | -483.04 Thousand CAD | 57.06% |
| 2015 Q3 | -1.12 Million CAD | -29.41% |
| 2015 Q2 | -869.29 Thousand CAD | 13.2% |
| 2014 FY | -3.48 Million CAD | -32.08% |
| 2014 Q4 | -473.34 Thousand CAD | 31.78% |
| 2014 Q3 | -693.81 Thousand CAD | 48.06% |
| 2014 Q2 | -1.33 Million CAD | -35.48% |
| 2014 Q1 | -985.98 Thousand CAD | -60.6% |
| 2013 Q4 | -613.92 Thousand CAD | -0.7% |
| 2013 FY | -2.63 Million CAD | 12.72% |
| 2013 Q2 | -724.75 Thousand CAD | -5.4% |
| 2013 Q1 | -687.65 Thousand CAD | 33.71% |
| 2013 Q3 | -609.63 Thousand CAD | 15.89% |
| 2012 Q3 | -588.11 Thousand CAD | 24.5% |
| 2012 Q2 | -778.91 Thousand CAD | -44.04% |
| 2012 FY | -3.02 Million CAD | -39.22% |
| 2012 Q1 | -540.74 Thousand CAD | 49.32% |
| 2012 Q4 | -1.03 Million CAD | -76.38% |
| 2011 Q2 | -506.82 Thousand CAD | -9.97% |
| 2011 Q3 | -491.38 Thousand CAD | 3.05% |
| 2011 Q1 | -460.86 Thousand CAD | 3.43% |
| 2011 FY | -2.16 Million CAD | -102.82% |
| 2011 Q4 | -1.06 Million CAD | -117.13% |
| 2010 Q1 | -202.62 Thousand CAD | 28.2% |
| 2010 Q4 | -477.22 Thousand CAD | -127.36% |
| 2010 Q2 | -179.52 Thousand CAD | 11.4% |
| 2010 Q3 | -209.89 Thousand CAD | -16.92% |
| 2010 FY | -1.06 Million CAD | 12.78% |
| 2009 Q2 | -667.09 Thousand CAD | -783.82% |
| 2009 Q3 | -201.63 Thousand CAD | 69.77% |
| 2009 FY | -1.22 Million CAD | -838.3% |
| 2009 Q4 | -282.2 Thousand CAD | -39.96% |
| 2009 Q1 | -75.47 Thousand CAD | -110.64% |
| 2008 Q4 | -35.83 Thousand CAD | -57.98% |
| 2008 Q3 | -22.68 Thousand CAD | 52.29% |
| 2008 FY | -130.7 Thousand CAD | 45.1% |
| 2008 Q1 | -24.75 Thousand CAD | 18.15% |
| 2008 Q2 | -47.54 Thousand CAD | -92.03% |
| 2007 FY | -238.06 Thousand CAD | -3967650.0% |
| 2007 Q3 | -23.32 Thousand CAD | 39.87% |
| 2007 Q1 | -145.69 Thousand CAD | 0.0% |
| 2007 Q4 | -30.24 Thousand CAD | -29.66% |
| 2007 Q2 | -38.79 Thousand CAD | 73.37% |
| 2006 FY | -6.00 CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.501% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 151.109% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.687% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 85.925% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.069% |
| Mesoblast Limited | -84.14 Million USD | 97.015% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -63.532% |
| Genus plc | 6.4 Million USD | 139.249% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 125.783% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -169.7% |
| Marizyme, Inc. | -34.08 Million USD | 92.631% |
| ContraFect Corporation | -56.88 Million USD | 95.584% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 69.917% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 44.85% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -79.169% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | 11.878% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | 8.685% |
| MultiCell Technologies, Inc. | -722.81 USD | -347423.554% |
| Accustem Sciences Inc. | -3.74 Million USD | 32.951% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.742% |
| EV Biologics, Inc. | -483.06 Thousand USD | -420.003% |
| Q BioMed Inc. | -3.44 Million USD | 27.098% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 170.959% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -544.797% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | 4.399% |
| Biomind Labs Inc. | -1 Million USD | -148.804% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 48.521% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 62.215% |
| Skye Bioscience, Inc. | -13.67 Million USD | 81.627% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -26.452% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -8286.535% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 50.204% |
| IMV Inc. | -38.67 Million USD | 93.504% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 84.172% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -29.976% |
| GB Sciences, Inc. | -1.42 Million USD | -76.833% |
| Alpha Cognition Inc. | -9.7 Million USD | 74.119% |
| HST Global, Inc. | -140.9 Thousand USD | -1682.69% |
| CSL Limited | 3.7 Billion USD | 100.068% |
| Halberd Corporation | -75.05 Thousand USD | -3247.015% |
| Enzolytics Inc. | -2.14 Million USD | -16.899% |
| Resverlogix Corp. | -12.74 Million USD | 80.297% |
| Affymax, Inc. | -15.04 Million USD | 83.305% |
| SYBLEU INC | -149.18 Thousand USD | -1583.828% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 20.716% |
| argenx SE | -425.04 Million USD | 99.409% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 95.475% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -140.607% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -59.048% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 26.228% |
| AVAX Technologies, Inc. | 6.69 Million USD | 137.531% |
| Zenith Capital Corp. | -8.94 Million USD | 71.912% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.396% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -14319.006% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -2.306% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1364.604% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 95.431% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 13.419% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -155.264% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -34.734% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -99.995% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -25.299% |
| BioStem Technologies, Inc. | -7.77 Million USD | 67.709% |
| ONE Bio Corp. | 13.68 Million USD | 118.36% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1284.101% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -88.099% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -123.302% |
| Agentix Corp. | -1.37 Million USD | -83.118% |
| LadRx Corporation | -3.82 Million USD | 34.305% |
| Cell Source, Inc. | -4.32 Million USD | 41.925% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -504.588% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -265.665% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -265.665% |
| NovAccess Global Inc. | -2.46 Million USD | -1.831% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 13.958% |
| Itoco Inc. | -919.14 Thousand USD | -173.292% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 40.734% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -124.48% |
| Kadimastem Ltd | -3.04 Million USD | 17.377% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -859.758% |
| CytoDyn Inc. | -18.05 Million USD | 86.09% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -9879.877% |
| Mobile Lads Corp. | -554.55 Thousand USD | -352.968% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1041.384% |
| Qrons Inc. | -643.67 Thousand USD | -290.248% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -344.808% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -12.649% |
| Rebus Holdings, Inc. | -664 Thousand USD | -278.303% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -38.298% |
| International Stem Cell Corporation | -663 Thousand USD | -278.874% |
| Bioxytran, Inc. | -3.82 Million USD | 34.245% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -4671.913% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -12249.73% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 93.074% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -55.249% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -241.372% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 19.256% |
| Neutra Corp. | -229.48 Thousand USD | -994.592% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 85.678% |
| PureTech Health plc | -146.19 Million USD | 98.282% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 88.312% |
| IXICO plc | -1.43 Million USD | -74.804% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 73.534% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.938% |
| CSL Limited | 3.81 Billion USD | 100.066% |
| Cellectis S.A. | -108.85 Million USD | 97.692% |